Los datos más relevantes de ESMO sobre el CPNM en estadios avanzados

En este primer bloque, el Dr. Carcereny, junto a la Dra. Bernabé y al Dr. de Castro repasarán el paradigma de tratamiento en los estadios avanzados, comentando los datos presentados en ESMO del EMPOWER-Lung 01, Keynote-189 y 407 IPSOS, POSEIDON y MEDI5752

Ozguroglu M, et al. LBA54 presented at ESMO 2022. Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

Ming Lee S, et al. LBA11 presented at ESMO 2022. IPSOS: Results from a Phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

Jhonson M.L., et al. LBA59 presented at ESMO 2022. Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

Ahn M, et al. LBA56 presented at ESMO 2022. MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

Garassino M.C., et al. Abstract 973MO presented at ESMO 2022. KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC

Novello S, et al. Abstract 974MO presented at ESMO 2022. 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)